Zobrazeno 241 - 250
of 162 694
pro vyhledávání: ''
Autor:
Didier, Debieuvre, Charles, Dayen, Adrien, Dixmier, David, Pau, Anna, Sibley-Revelat, William, Greenwood, Samuel, Gally, Lionel, Falchero
Publikováno v:
Lung Cancer. 164:1-7
FRESC reanalyzed extensive-stage small-cell lung cancer (ES-SCLC) patient data from the French KBP-2010 cohort to describe the characteristics and therapeutic management of ES-SCLC and provide real-world estimates of survival.A target population of f
Autor:
Hong Luo, Yi Hu, Patricia Keegan, Hongqian Guo, Ji-Yan Liu, Haige Chen, Sheng Yao, Weifeng Wang, Jun Guo, Fangjian Zhou, Xudong Yao, Benkang Shi, Zhigang Ji, Hui Feng, Xinan Sheng, Zhisong He, Bin Hu, Ziling Liu, Jin Wu, Xin Yao, Jinhai Fan, Yiran Huang
Publikováno v:
Clinical Cancer Research. 28:489-497
Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety, efficacy
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Autor:
C. Meyer, Y. Fouché, Emmanuel Chamorey, M. Dejode, C. Bailleux, J. Haudebourg, Renaud Schiappa, Y. Delpech, Emmanuel Barranger
Publikováno v:
Clinical Breast Cancer. 22:121-126
Background Delays in initiating adjuvant chemotherapy after breast cancer surgery seems to have an impact on patients’ risk of relapse and their survival rate. The aim of this retrospective study was to identify factors delaying initiation of adjuv
Autor:
Scott R. Solomon, Richard J. O'Reilly, Sergio Giralt, Raquel Palencia, Lori Muffly, Leyla Shune, Miguel-Angel Perales, Brent R. Logan, Mary M. Horowitz, Marcelo C. Pasquini, Nancy L. Geller, Richard J. Jones, Leo Luznik, Adam Mendizabal, Sumithira Vasu, Juan Wu, Johannes Schetelig, Steven M. Devine, Helen E. Heslop, Lynn O'Donnell, Eneida R. Nemecek, Mark R. Litzow, Robert J. Soiffer, Vincent T. Ho
Publikováno v:
J Clin Oncol
PURPOSE Calcineurin inhibitors (CNI) are standard components of graft-versus-host disease (GVHD) prophylaxis after hematopoietic cell transplantation (HCT). Prior data suggested that CNI-free approaches using donor T-cell depletion, either by ex vivo
Autor:
Laura Sellmer, Julia Kovács, Jens Neumann, Julia Walter, Diego Kauffmann-Guerrero, Zulfiya Syunyaeva, Jan Fertmann, Christian Schneider, Julia Zimmermann, Juergen Behr, Amanda Tufman
Publikováno v:
Future Oncology. 18:481-489
Aim: To analyze immune cell populations in non-small-cell lung cancer (NSCLC) tumors and matched tumor-bearing and non-tumor-bearing lymph nodes (ntbLNs) to predict prognosis. Patients & methods: 71 patients with long-term disease-free survival and 8
Publikováno v:
Clinical Breast Cancer. 22:e232-e238
Objective To evaluate factors contributing to positive surgical margins associated with reflector guidance for patients undergoing breast conserving therapy for malignancy. Materials and Methods A retrospective IRB-approved review of our institutiona
Publikováno v:
Future Oncology. 18:679-690
Objective: D-dimer is correlated to the poor prognosis of non-small-cell lung cancer. The study aimed to investigate the association between plasma D-dimer and concomitant mutations in non-small-cell lung cancer. Methods: A total of 517 non-small-cel
Autor:
Rebecca L Stone, M Janelle Cambron-Mellott, Kathleen Beusterien, Martine C Maculaitis, Stephanie Ritz, Emily Mulvihill, Matthew Monberg, Elizabeth A Szamreta, Suvina Amin, Kimmie McLaurin
Publikováno v:
Future Oncology. 18:491-503
Plain language summary Maintenance therapy is a treatment option intended to keep ovarian cancer from coming back or getting worse for as long as possible after responding to chemotherapy. PARP inhibitors are a new type of maintenance therapy for ova
Autor:
Julie Means-Powell, Luis Del Valle, Vandana G. Abramson, Claudia Sorrentino, Melinda Sanders, Ingrid A. Mayer, Debra A. Tonetti, Roohi Ismail-Khan, Samarpan Majumder, Richard M Lush, Lucio Miele
Publikováno v:
Clin Breast Cancer
Preclinical studies have demonstrated a complex cross-talk between Notch and estrogen signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational agents that block the cleavage and activation of Notch receptors. In